Literature DB >> 2785396

Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines.

P J Guillou1, C W Ramsden, S S Somers, P C Sedman.   

Abstract

Serum-free supernatants from in vitro maintained gastrointestinal cancer and melanoma cell lines inhibit the generation of lymphokine (IL-2) activated killer (LAK) cells in a time and dose-related manner. Concentrations as low as 5% can inhibit the generation of LAK cytotoxicity but inhibition of proliferation is not observed until higher concentrations are included in the culture system. Inhibition is not observed with supernatants from a breast cancer cell line nor with supernatants from normal cells. There was complete concordance between the capacity of the tumour cells themselves to inhibit LAK generation and the presence of inhibitory activity in the corresponding supernatant. The inhibitory factor(s) is stable after heating to 44 and 56 degrees C. Production of the inhibitory factor(s) is sensitive to metabolic inhibitors and has a molecular weight greater than 25 kD. The inhibition of LAK cell stimulation by tumour cells may partially explain the failure of adoptively transferred LAK cells and IL-2 therapy to cause tumour regression in man.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785396      PMCID: PMC2247131          DOI: 10.1038/bjc.1989.106

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  41 in total

1.  The effect of interferon-gamma treatment of rat tumour cells on their susceptibility to natural killer cell, macrophage and cytotoxic T-cell killing.

Authors:  H Yeoman; R A Robins
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

2.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.

Authors:  R U de Fries; S H Golub
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

4.  Production of transforming growth factors by human colon cancer lines.

Authors:  R J Coffey; G D Shipley; H L Moses
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

5.  Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.

Authors:  S Miescher; T L Whiteside; S Carrel; V von Fliedner
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

6.  Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.

Authors:  R R Salup; R H Wiltrout
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

7.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

8.  Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2.

Authors:  T L Whiteside; D S Heo; S Takagi; J T Johnson; S Iwatsuki; R B Herberman
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.

Authors:  A H Rook; J H Kehrl; L M Wakefield; A B Roberts; M B Sporn; D B Burlington; H C Lane; A S Fauci
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

10.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.

Authors:  J J Mulé; J Yang; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

View more
  6 in total

1.  Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cell-mediated immune response.

Authors:  P McCulloch; G Gallagher; L P Walsh; Y Zaloom; J Xie
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

2.  Comparison of transforming growth factor beta and a human tumour-derived suppressor factor.

Authors:  S S Somers; J F Dye; P J Guillou
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Effects of CD4+ and CD8+ T cells in tumor-bearing mice on antibody production.

Authors:  M Shimizu; T Iwaguchi
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 4.  The role of fibroblasts in tumor behavior.

Authors:  M Grégoire; B Lieubeau
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

5.  Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.

Authors:  W M Mulder; M J Stukart; M Roos; R A van Lier; J Wagstaff; R J Scheper; E Bloemena
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

6.  Expression of a suppressive p15E-related epitope in colorectal and gastric cancer.

Authors:  S Foulds; C H Wakefield; M Giles; J Gillespie; J F Dye; P J Guillou
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.